Oxaliplatin‐ and docetaxel‐induced polyneuropathy: clinical and neurophysiological characteristics. Issue 4 (6th October 2020)

• Record Type: Journal Article
• Authors: Bennedsgaard, Kristine; Ventzel, Lise; Andersen, Niels T.; Themistocleous, Andreas C.; Bennett, David L.; Jensen, Troels S.; Tankisi, Hatice; Finnerup, Nanna B.
• Is Part Of: Journal of the peripheral nervous system. Volume 25:Issue 4(2020)
• Page Start: 377
• Page End: 387
• Publication Date: 2020-10-06
• Subjects: assessment tools -- chemotherapy -- corneal confocal microscopy -- large fiber neuropathy -- motor unit number estimation -- nerve conduction study -- neuropathic pain -- neuropathy -- pain -- small fiber neuropathy; Nervous system -- Periodicals; Nerves, Peripheral -- Diseases -- Periodicals; Peripheral Nervous System Diseases -- Periodicals; Peripheral Nervous System -- Periodicals; 612.81
• DOI: 10.1111/jns.12413
• Languages: English
• ISSNs: 1085-9489

Abstract

Abstract: The aim of this study was to evaluate the presence and characterization of chemotherapy‐induced neuropathy (CIPN) and neuropathic pain 5 years after adjuvant chemotherapy with docetaxel or oxaliplatin. Patients from an ongoing prospective study, who had received adjuvant chemotherapy with docetaxel or oxaliplatin in 2011 to 2012 were invited to participate. The patients underwent a thorough examination with interview, neurological examination, questionnaires, assessment tools, nerve conduction studies (NCS), quantitative sensory testing, MScan motor unit number estimation (MUNE), and corneal confocal microscopy (CCM). Patients were divided into no, possible, probable, and confirmed CIPN. Out of the 132 eligible patients, 63 agreed to participate: 28 had received docetaxel and 35 had received oxaliplatin. Forty‐one percent had confirmed CIPN, 34% possible or probable CIPN, and 22% did not have CIPN. The CIPN was characterized mainly by sensory nerve fiber loss, with a more pronounced large fiber than small fiber loss but also some motor fiber loss identified on NCS and MUNE. In general, patients had mild neuropathy with relatively low scores on assessment tools and no association with mood and quality of life. CCM was not useful as a diagnostic tool. Of the patients with probable or confirmed CIPN, 30% experienced pain, which was most often mild, but still interfered moderately with daily life in 20% to 25% and was associated with lower quality of life. In conclusion CIPN was confirmed in 41% 5 years after chemotherapy. The neuropathy was generally mild, but in patients with neuropathic pain it was associated with lower quality of life.